Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersBrief Review
You have accessRestricted Access

Regulated Cell Death in AKI

Andreas Linkermann, Guochun Chen, Guie Dong, Ulrich Kunzendorf, Stefan Krautwald and Zheng Dong
JASN December 2014, 25 (12) 2689-2701; DOI: https://doi.org/10.1681/ASN.2014030262
Andreas Linkermann
*Clinic for Nephrology and Hypertension, Christian-Albrechts-University, Kiel, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guochun Chen
†Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guie Dong
‡Department of Cellular Biology and Anatomy, Charlie Norwood Veterans Affairs Medical Center and Medical College of Georgia at Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Kunzendorf
*Clinic for Nephrology and Hypertension, Christian-Albrechts-University, Kiel, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Krautwald
*Clinic for Nephrology and Hypertension, Christian-Albrechts-University, Kiel, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Dong
†Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; and
‡Department of Cellular Biology and Anatomy, Charlie Norwood Veterans Affairs Medical Center and Medical College of Georgia at Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

AKI is pathologically characterized by sublethal and lethal damage of renal tubules. Under these conditions, renal tubular cell death may occur by regulated necrosis (RN) or apoptosis. In the last two decades, tubular apoptosis has been shown in preclinical models and some clinical samples from patients with AKI. Mechanistically, apoptotic cell death in AKI may result from well described extrinsic and intrinsic pathways as well as ER stress. Central converging nodes of these pathways are mitochondria, which become fragmented and sensitized to membrane permeabilization in response to cellular stress, resulting in the release of cell death–inducing factors. Whereas apoptosis is known to be regulated, tubular necrosis was thought to occur by accident until recent work unveiled several RN subroutines, most prominently receptor-interacting protein kinase–dependent necroptosis and RN induced by mitochondrial permeability transition. Additionally, other cell death pathways, like pyroptosis and ferroptosis, may also be of pathophysiologic relevance in AKI. Combination therapy targeting multiple cell-death pathways may, therefore, provide maximal therapeutic benefits.

  • acute renal failure
  • apoptosis
  • renal injury

AKI is a multifactorial and multiphasic renal disease characterized by a rapid decline of renal function, resulting in the accumulation of metabolic waste and toxins and consequent complications and failure of other organs. Clinically, the causes of AKI mainly include sepsis, ischemia-reperfusion (IR) injury, and various endogenous as well as exogenous nephrotoxins. It is estimated that over 2 million people die of AKI each year around the world,1 and the prevalence of AKI has been increasing rapidly.1,2 AKI is also known for its association with unacceptably high rates of mortality. For example, in intensive care units, AKI is associated with a mortality rate of 50%–80%. Notably, even if the patients survived, the post-AKI prognosis is dismal, with 7.5% requiring long-term dialysis and 30%–70% developing complications, including CKD and ESRD. The annual cost of AKI in the United States is estimated to exceed $10 billion.3,4

Pathologically, AKI is characterized by renal tubular damage, inflammation, and vascular dysfunction. Injury and death of tubular cells are especially recognized as the precipitating factors in AKI, and as an extension, tubular repair and regeneration are considered major events in kidney recovery from AKI.5–8 Although sublethal injury is reversible, the death of tubular cells is accompanied by the inevitable loss of the function of the affected cells, and notably, it is also frequently the source of damage-associated molecular patterns (DAMPs), the stimulating and amplifying factors of inflammation in tissue damage.9 In AKI, various forms of cell death are noticeable: necrosis and apoptosis. This review summarizes the evidence for the various forms of regulated cell death in AKI, delineates their underlying mechanisms with an emphasis on the new insights, and puts forth the perspectives of targeting cell death for the prevention and therapy of kidney injury.

Apoptosis—the Classic View of Regulated Cell Death in the Kidney

Evidence for Apoptosis in AKI

In 1992, Schumer et al.10 showed DNA cleavage and nuclear condensation during renal IR injury, showing the first evidence of apoptosis in AKI. To date, the initial observation has been confirmed and extensively expanded. By morphology, apoptotic cells are identified after renal IR by electron microscopy and various nuclear staining methods.10–12 Biochemically, renal IR leads to the activation of caspases and endonucleases.13,14 In addition, regulation of apoptotic genes, including caspases and Bcl-2 family proteins, has been shown.13–16

TUNEL staining and the evaluation of in vivo cell death. TUNEL has been widely used within the last two decades to evaluate cell death in tissues. Indeed, most dead cells stain positive for TUNEL, because double-strand breaks are found in most programmed cell death. Obviously, TUNEL positivity is found in apoptotic cells, but in contrast to the widespread belief, TUNEL positivity is not limited to apoptosis, because the cells of regulated necrosis are TUNEL-positive as well.173 Therefore, detection of apoptosis requires additional staining (e.g., cleaved caspase 3 [also referred to as activated caspase 3]) either from tissue lysates in Western blot assays or immhunohistochemically. The difference between TUNEL staining and positivity for cleaved caspase 3 might even be used to quantify the amount of regulated necrosis in tissues,173 but it cannot further specify the precise pathway of regulated necrosis.174 To further distinguish necroptosis from apoptosis, one emerging marker for the direct detection of necroptosis is an mAb that detects phosphorylated MLKL.114 This antibody, however, only detects human phosphorylated MLKL.

Apoptosis is also well recognized in AKI induced by various nephrotoxins. For example, cisplatin is a widely used cancer therapy drug with a major side effect of nephrotoxicity, which limits it therapeutic efficacy.17,18 Depending on the dosage, cisplatin induces both necrosis and apoptosis in renal tubular cells in vitro as well as in vivo in animal models. Apoptosis is shown by cell morphology, caspase activation, and terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) assay of DNA damage. Renoprotection against cisplatin nephrotoxicity is associated by the suppression of tubular cell apoptosis,19–24 further supporting the involvement of apoptosis in cisplatin-induced renal injury. In human kidneys of sepsis-associated AKI, tubular cell apoptosis is detected by TUNEL and activated caspase 3 staining.25 Of note, in some of the previous studies, apoptosis was detected in kidney tissues by a single method, such as TUNEL assay, which may be questionable for its specificity of apoptosis (Box).

In addition, although tubular apoptosis has often been reported in various models of AKI, the upstream signaling pathways leading to apoptosis in these models can be very different. For example, distinct pathogenic mechanisms may be responsible for apoptosis in ischemic and cisplatin nephrotoxic AKI.26,27

In AKI, apoptotic cells are shown in both cortical and medullary regions. In renal tubules, apoptosis occurs in proximal tubules, distal tubules, and tubular cells of the Henle’s loop.10,12,28–36 Numerous renoprotective agents seem to ameliorate AKI, at least in part, by diminishing tubular apoptosis. For example, minocycline, a tetracycline derivative, blocks apoptosis during renal IR, which is accompanied by the amelioration of ischemic renal injury and renal failure.28,37 Remarkably, deletion of apoptotic genes specifically from proximal tubules results in marked decreases in apoptosis and protection from both ischemic and nephrotoxic AKI.38,39 Together, these studies show an important role of tubular cell apoptosis in AKI.

Main Pathways of Apoptosis in AKI

Apoptosis can be initiated through several pathways (Figure 1). In the intrinsic pathway, cell stress directly leads to mitochondrial outer membrane permeabilization (MOMP), resulting in the release of apoptogenic factors, including cytochrome c, that then bind Apaf-1 to activate caspase 9. In the extrinsic pathway, ligation of death receptors leads to the recruitment of adapter proteins and subsequent activation of caspase 8.40 Under endoplasmic reticulum (ER) stress, caspase 12 is activated,41 and more recent studies suggested that caspase 2 can be an initiator caspase for apoptosis.42

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Pathways of apoptosis. In the intrinsic apoptotic pathway, cellular stress leads to the oligomerization of Bax and Bak, an event that permeabilizes the mitochondrial outer membrane, resulting in the release of apoptogenic factors, including cytochrome c (Cyt.c). In the cytosol, Cyt.c binds Apaf-1 to recruit and activate caspase 9, which further cleaves and activates executioner caspases, such as caspase 3. In the extrinsic apoptotic pathway, ligation of death receptors leads to the recruitment of adapter proteins and subsequent activation of caspase 8, which further activate executioner caspases and prevent necroptosis (Figure 4). Active caspase 8 also cleaves Bid to its truncated form tBid, which translocates to mitochondria to activate the intrinsic pathway to amplify the apoptotic cascade. In the ER stress pathway, caspase 12 mediates the activation of executioner caspases. ER stress may activate the intrinsic apoptotic pathway through Ca2+ signaling and the induction of proapoptotic Bcl-2 family proteins, such as PUMA. IP3R, inositol trisphosphate receptor.

All aforementioned apoptotic pathways have been implicated in AKI. The extrinsic pathway of apoptosis mediated by TNF-α and Fas may contribute to tubular cell loss in ischemic and septic AKI.43–45 Consistently, TNF-α receptor knockout mice are resistant to cisplatin AKI, further supporting the involvement of the TNF-α–mediated extrinsic pathway in the pathogenesis of AKI.46 In ischemic and cisplatin nephrotoxic AKI, ER stress activation has been documented, but definitive evidence for the involvement in ER stress–related apoptosis has yet to be shown.47,48 In contrast, the role played by the intrinsic pathway of apoptosis in AKI has been shown convincingly. In 1998, evidence of the activation of the intrinsic pathway in AKI was shown by using the experimental model of hypoxic incubation of renal tubular cells.49 In this model, cytochrome c is released from mitochondria followed by caspase activation and tubular cell apoptosis. Importantly, the activation of Bax and Bak, two proapoptotic Bcl-2 family proteins, was later confirmed to be key to the mitochondrial leakage or MOMP.49–51 In animals, MOMP associated by cytochrome c release was shown during ischemia and cisplatin nephrotoxic AKI.33,37,52 The critical roles of Bax and Bak in AKI have been shown recently using global and proximal tubule–specific gene knockout models.39 Notably, in humans, mitochondrial damage by Bax and Bak seems to be a key to apoptotic cell death in kidneys injured by ischemia.53,54 Upregulation of Bcl-2 either pharmacologically or by gene transfection consistently blocks Bax and Bak activation, resulting in the preservation of mitochondrial integrity and cell viability and further supporting a critical role of the intrinsic pathway of apoptosis in tubular injury in AKI.28,49–51

Mitochondria and Bcl-2 Proteins: Central Players in Apoptosis

Despite the different initiation mechanisms, most (if not all) apoptotic pathways converge on mitochondria (Figure 1). Although the extrinsic pathway of apoptosis is initiated by ligand binding of death receptors, caspase 8 (after being activated in this pathway) can activate the intrinsic pathway of apoptosis through Bcl-2 family proteins.55,56 Mitochondria also play an important role in apoptosis initiated by ER stress and caspase 2.57,58 Thus, mitochondrial damage characterized by MOMP is considered a central control point of apoptosis.59,60

At the molecular level, Bcl-2 family proteins are the key regulators of mitochondrial integrity. Defined by the presence of Bcl-2 homology (BH) domains, Bcl-2 family proteins can be proapoptotic or antiapoptotic.59,61–63 Specific functions of individual Bcl-2 proteins are dictated by the organization of the BH domains. Accordingly, antiapoptotic members, like Bcl-2 and Bcl-XL, usually contain four BH domains. Proapoptotic members can be further divided into two groups: multi-BH domain proteins, such as Bax and Bak, and BH3-only proteins, such as Bid and PUMA.59,61–63 Antiapoptotic Bcl-2 proteins protect cells by preserving the integrity of mitochondria, whereas the proapoptotic molecules kill cells by permeabilizing the organelles.59,61–63 Notably, Bax and Bak provide a requisite gateway to mitochondrial injury in various apoptotic models.64 Deletion of Bax and/or Bak consitently leads to a marked resistance to tubular apoptosis in AKI.39,65

Despite the significance of Bax and Bak in mitochondrial injury during apoptosis, the mechanism underlying their activation remains elusive. Normally, Bax is cytosolic, whereas Bak resides on the mitochondrial outer membrane. On cell stress or apoptosis, Bax translocates to mitochondria, inserts to the outer membrane, and forms oligomers. Meanwhile, Bak is also activated to oligomerize. Bax activation may involve the interaction with specific proteins, such as Bid, p53, humanin, 14-3-3 protein, ku70, and Bif-1.66–72 In renal tubular cells, Borkan and colleagues73 have recently shown the interaction of nucleophosmin with Bax, which seems to be critical to Bax activation during metabolic stress in vitro and ischemic AKI in vivo. As discussed below, the activation of Bax and Bak also involves a striking change of mitochondrial morphology and consequent alterations of the membrane property.

Mitochondrial Dynamics in Apoptosis and AKI

Mitochondrion, of the Greek mito for thread and chondro for grain, assumes distinct morphologies. Recent research has further revealed that mitochondria are a class of highly dynamic organelles.74,75 Whether mitochondria display a filamentous morphology or punctiform is determined by two opposing processes: fission and fusion. Accordingly, fusion of mitochondria promotes a filamentous network, whereas fission fragments mitochondria into short rods or spheres. In mammalian cells, mitochondrial fusion involves mitofusin-1, mitofusin-2, and OPA1, whereas fission depends on Drp-1, Fis-1, and others.

In 2001, Youle and colleagues76 reported that mitochondrial dynamics are lost on cell stress or apoptosis, leading to the fragmentation of mitochondria. Importantly, inhibition of mitochondrial fragmentation blocks cytochrome c release and apoptosis. In vivo in diseases, the role of mitochondrial fragmentation was first suggested by using experimental models of ischemic and cisplatin nephrotoxic AKI. Under these conditions, Drp1 translocates to mitochondria, which is followed by sequential events of mitochondrial fragmentation, Bax/Bak activation, cytochrome c release, caspases activation, and apoptosis. Blockade of Drp1 pharmacologically or genetically preserves the filamentous morphology of mitochondria, resulting in the suppression of tubular cell apoptosis and amelioration of AKI.77 These findings have been extended to other disease conditions, such as IR injury in the heart and brain,78,79 supporting mitochondrial fragmentation as a general pathogenic mechanism.

Mitochondrial fragmentation is the result of the disruption of mitochondrial dynamics. On cell stress, Drp-1 is activated (as indicated by its translocation to mitochondria) to accelerate fission. The regulation of Drp1 involves multiple post-translational modifications. In models of AKI, Drp1 is rapidly dephosphorylated in renal tubular cells, likely through calcineurin family phosphotases.80 Prevention of Drp1 dephosphorylation by calcineurin inhibitors can partially block mitochondrial fragmentation, cytochrome c release, and apoptosis, supporting a role of the dephosphorylation in Drp1 activation and mitochondrial fission.80 Interestingly, mitochondrial fragmentation not only involves hyperactivation of fission but also, depends on the arrest of fusion. Intriguingly, fusion arrest is governed by the interaction of mitofusins with Bak.81 Normally, Bak binds both mitofusin-1 and mitofusin-2. On cell stress or apoptosis, Bak dissociates from mitofusin-2 and binds mitofusin-1 at a higher affinity. Remarkably, a Bak mutant incapable of dissociating from mitofusin-2 cannot induce mitochondrial fragmentation,81 suggesting that Bak contributes to mitochondrial fragmentation by switching its binding from mitofusin-2 to mitofusin-1 (Figure 2). This key finding has been confirmed in experimental models of oxidative lung injury.82 A role of Bak in mitochondrial fragmentation has further been shown in vivo in AKI models by using gene knockout mice.39 Thus, mitochondrial fragmentation is a combined result of fission activation by Drp1 and fusion arrest mediated by Bak interaction with mitofusins.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Mitochondrial dynamics in apoptosis. Under normal in vivo conditions, Bax and Drp1 are located within the cytosol, whereas Bak is at the mitochondrial outer membrane, where it binds both mitofusin-1 (Mfn1) and mitofusin-2 (Mfn2) to maintain mitochondrial fusion, ensuring its filamentous morphology. On cellular stress, Drp1 translocates to mitochondria, where it forms a restriction ring to activate the cleavage of the organelles; meanwhile, Bak dissociates from Mfn2 to bind Mfn1, which leads to an arrest of fusion and mitochondrial fragmentation. Fragmented mitochondria are more sensitive to Bax oligomerization, resulting in outer membrane permeabilization followed by the release of apoptogenic factors, such as cytochrome c (cyt.c), to activate the intrinsic apoptotic pathway. In addition, mitochondrial fragmentation may also contribute to MPT, leading to necrosis.

Of note, mitochondrial fragmentation is initially reversible; in other words, fragmented mitochondria can refuse if the insult is removed from the cell in time. Then how can mitochondrial fragmentation, a seemingly morphologic change, affect mitochondrial injury? The answer may be in the changes of mitochondrial membrane properties that occur as a result of the loss of mitochondrial dynamics. It has been shown that fragmented mitochondria are sensitized to Bax insertion and oligomerization.83 Thus, mitochondrial fragmentation may participate in apoptosis by facilitating Bax insertion and oligomerization, resulting in outer membrane permeabilization and leakage of apoptogenic factors, such as cytochrome c. In addition, mitochondrial fragmentation may contribute to mitochondrial permeability transition (MPT) at the inner membrane, resulting in necrosis (Figure 2). In kidneys, mitochondrial fragmentation as a result of the disruption of mitochondrial dynamics contributes to not only AKI but also other renal diseases, including diabetic nephropathy.84,85

Regulated Necrosis

Necrosis is distinguished from apoptosis by the breakdown of the integrity of the plasma membrane. As such, necrotic cell death is accompanied by the release of unprocessed intracellular content, including cellular organelles, highly immunogenic proteins, like IL-33, F-actin, ATP, IL-1α, and HMGB1, double-stranded DNA, and RNA.86 These proimmunogenic cellular components are collectively referred to as DAMPs.86,87 The dynamics of DAMP release in the kidney have recently been shown by intravital microscopy.88 Although originally thought to be accidental, recent work has revealed several pathways of genetically determined and regulated necrosis89,90 (Figure 3), and we are beginning to understand the relative contribution of these pathways with presumably overlapping function (see below). On the molecular level, the best characterized pathway of regulated necrosis is necroptosis, an receptor-interacting protein kinase–based necrotic cell death.91

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Necrotic cell death in renal tubular epithelial cells. Four-phase model of necrosis-associated release of DAMPs. (A) Tubular epithelial cell layer under physiologic conditions. (B) On induction of regulated necrosis as the common mechanism of several distinct intracellular signaling pathways, individual cells begin to swell on specific genetically-determined intracellular programs that decode for regulated necrosis (like necroptosis, MPT-mediated regulated necrosis, pyroptosis, or ferroptosis). (C) Severe swelling of the luminal part of a tubular cell that undergoes regulated necrosis. (D) Plasma membrane rupture associated with DAMP release. Regulated necrosis might, therefore, trigger subsequent detrimental immune responses that cause additional organ damage beyond the primary loss of function from cell death. In transplanted organs, a classic setting for IR injury, DAMPs released from necrotic cells might trigger rejection, despite the state of immunosuppression.

Necroptosis—a Paradigm Shift

The in vivo relevance of necroptosis has been undoubtedly clarified by the rescue of caspase 8–deficient mice by ablation of receptor-interacting protein kinase 3 (RIPK3).92,93 Whereas caspase 8–deficient mice die at day 10.5 in utero and RIPK3-deficient mice have been described without phenotype,94 caspase 8/RIPK3 double-deficient mice are born at expected Mendelian frequencies and show a phenotype that was previously described as lymphoproliferation or generalized lymphoproliferative disease in mice that carry mutations in the Fas-Fas ligand pathway.92,93 From these groundbreaking experiments, it became obvious that the most important function of caspase 8 is the prevention of necroptotic cell death by a caspase 8/FLIP long heterodimer93,95 rather than the induction of either apoptosis by the caspase 8 homodimer96,97 or inflammation, possibly mediated by single caspase 8 molecules.98 In addition, from these studies, an in vivo model emerged that allows for direct investigation of mice deficient in extrinsic (receptor-mediated) apoptosis.

The signaling pathway of necroptosis has been reviewed in detail recently.90,99 Briefly, the main events that trigger necroptosis are engagement of death receptors in the presence of caspase inhibition,100,101 stimulation of Toll-like receptors,92,102 signaling through interferons,103,104 or recognition of intracellular viruses by the protein DAI.105,106 Any of these initial triggers uses an receptor-interacting protein–homotypic interacting motif (RHIM) domain to activate the kinase RIPK3, an essential mediator of necroptosis,107–109 which itself contains an RHIM domain and phosphorylates the downstream pseudokinase110 mixed lineage kinase domain–like (MLKL).111,112 Phosphorylation of MLKL by RIPK3 leads to a molecular switch mechanism, which exposes the N-terminal portion of MLKL113 to induce plasma membrane rupture.114

In the kidney, necroptosis was first suggested in renal ischemic AKI by showing a protective effect of necrostatin-1 (Nec-1), an inhibitor of RIPK1 (the bona fide upstream activator of RIPK3 in the necroptosis pathway) (Figure 4).115 Other groups have subsequently confirmed a role for Nec-1 in tubular cells,116–118 and the protection of RIPK3-deficient mice was shown in ischemic and cisplatin-induced AKI.27 Importantly, caspase 8/RIPK3–double knockout mice did not provide additional protection in the ischemic model but did in the cisplatin model, suggesting that, unlike previously suggested,119 extrinsic apoptosis may be of minor importance in IR injury but significantly contributes to cisplatin-induced AKI.27 This assumption is further underscored by the absence of a protective effect of the pancaspase inhibitor zVAD in the model of IR injury,115 whereas zVAD does prolong overall survival after a lethal bolus of cisplatin.27 In support of this concept, cyclosporin-mediated tubular damage120 or contrast-mediated AKI121 have been reported to be prevented by Nec-1. It should be mentioned, however, that, in these two cases, a clear detection of cell death failed and that it cannot formally be excluded that Nec-1, other than its obvious effects on necroptotic cell death, might also affect peritubular blood flow by uncharacterized means. In this sense, it is noteworthy that the highest expression of RIPK3, which is thought to indicate the cellular sensitivity of necroptosis,108 was found in glomerular endothelial cells rather than tubular cells.115

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Model of the integrated molecular signaling pathways of regulated necrosis in renal tubular cells. Four separate pathways of regulated necrosis may contribute to the overall organ damage in AKI. The common downstream mechanism that precedes necrotic cell death is apical swelling, which ultimately induces plasma membrane rupture as recently shown by intravital microscopy. RIPK1/RIPK3-dependent necroptosis has been extensively investigated in the kidney and is triggered by death receptors. RIPK3 is activated by phosphorylation and in turn, phosphorylates the pseudokinase MLKL, which has been suggested to be involved in the opening of plasma membrane calcium channels. Calcium-activated chloride and sodium channels may subsequently open to increase NaCl permeability, which may then cause water influx, cellular volume expansion, and plasma membrane rupture. Ca2+ from this source and others might also be involved in MPT, which directly causes regulated necrosis by unknown means. MPT and necroptosis have been clearly shown to exhibit two separate pathways in AKI. Inhibition of the cell surface cystine/glutamate antiporter system Xc-minus depletes intracellular cystine, which is reduced to cysteine on the intracellular side and together with glycine and glutamate, required for the synthesis of glutathione (GSH). Permanent hydrogen peroxide (H2O2) synthesis, especially in stressed cells, requires the GSH-dependent activity of glutathione peroxidase 4 (GPX4) to prevent H2O2-mediated lipid peroxidation followed by necrotic cell death. Finally, Toll-like receptors (TLRs) are activated by DAMPs or pathogen-associated molecular patterns (PAMPs) and crystals. TLRs activate inflammasomes, which induce caspase 1–dependent maturation of the proinflammatory cytokines IL-1β and IL-18. In parallel, inflammasomes trigger caspase 11–mediated cellular swelling and necrotic cell death, which is referred to as pyroptosis. The combination of DAMP release by necrosis and cytokine maturation renders pyroptosis an even higher immunogenic entity compared with the other pathways of regulated necrosis. Necroptosis can be prevented by the RIPK1 inhibitor Nec-1, its more stable variant, or the human-specific MLKL inhibitor necrosulfonamide (NSA). MPT can be inhibited by cyclosporin (CsA) or sanglifehrin A (SfA), ferroptosis is blocked by the small molecule ferrostatin-1 (Fer-1), and broad spectrum caspase inhibitors (e.g., zVAD-fmk) interfere with pyroptosis signaling. C. rodentium, Citrobacter rodentium; cys, Cysteine; E. coli, Escherichia coli; glu, glutamate; L pneumophila, Legionella pneumophila; V. cholerae, Vibrio cholerae.

Recently, RIPK3-deficient mice have been investigated in the model of adriamycin (ADR)-induced podocytes injury.122 As expected from previous investigations on the level of RIPK3 expression in podocyte cell lines,115 RIPK3 deficiency did not prevent ADR-induced proteinuria compared with wild-type mice but strongly prolonged overall survival in this model, unless the highest concentrations of ADR were used. Obviously, ADR-induced lethality depends on necroptosis, but it must be concluded that survival in this model is not dependent on podocyte injury, questioning the usefulness of this survival readout for podocyte damage. Taken together, necroptosis has, therefore, been shown to be critically involved in nephrotoxicity of cisplatin, cyclosporin, and ADR as well as, most notably, renal IR injury and kidney transplantation.

Necrosis by Mitochondiral Permeability Transition

Mitochondria are of outstanding interest and significance in cell death research.123,124 As outlined above, MOMP is regarded as the point of no return in the life and death decision during apoptosis.123,125 Interestingly, mitochondrial dysregulation, particularly in the form of MPT, is also capable of inducing necrotic cell death126 (Figure 2). MPT is a process that leads to the sudden exchange of solutes between the cytosol and the mitochondrial matrix through an elusive MPT pore (MPTP) that spans both the inner and outer mitochondrial membranes. The molecular composition of the MPTP remains elusive and a matter of debate.126–128 It is, however, generally accepted that the opening of the MPTP is regulated by the matrix protein cyclophilin D (CypD). In line with this finding, CypD-deficient mice have been shown to be protected from ischemic AKI.27,129,130 In addition, these mice are protected from cisplatin-induced AKI.27 Precise mechanisms about the regulation of the CypD-mediated opening of the MPTP remain unclear. In this regard, p53 has recently been suggested to be involved,131,132 but such reports are under debate.133 MPT was long known to be potentially targeted by either cyclosporin or sanglifehrin A in vitro and in vivo,27,134–136 and such effects might be of outstanding clinical importance, because trials have revealed a cyclosporin-sensitive role for MPT in myocardial infarction137; however, unfortunately, larger follow-up studies are still lacking. In addition, it is worth mentioning that there is yet another pathway of regulated necrosis called parthanatos89 because of its dependency on the nuclear protein PARP1.90 The in vivo relevance of parthanatos has been made very clear in both unilateral urethral obstruction and ischemic AKI.138,139 Future work on the potential overlay of parthanatos with MPT will be extraordinary helpful for untangling the complex web of interconnected pathways of regulated necrosis.

Pyroptosis—Maximal Immunogenicity of Necrosis

Pyroptosis is a necrotic-type cell death that was thought to occur exclusively in macrophages,140,141 but recent reports find comparable features in T lymphocytes,142 neurons,143 and tubular epithelial cells.144–147 The unique feature of pyroptosis compared with other pathways of regulated necrosis is the maturation of proinflammatory cytokines during the cell death process,148–150 which depends on cleavage mediated by nonapoptotic caspases. Many of the in vivo studies on pyroptosis have been performed in caspase 1–deficient mice, which have been described to carry a passenger mutation that functionally renders them caspase 1/11 double-deficient.151 It was not until the report of caspase 11–deficient mice that it was realized that caspase 11 mediates the pyroptotic cell death, whereas caspase 1 is thought to be mainly responsible for pro–IL-1β and pro–IL-18 cleavage.90 How caspase 11 mediates the downstream molecular events required for pyroptosis remains unclear, but in some similarity to necroptosis, it is speculated that plasma membrane channels are involved in the terminal cellular swelling.140 Caspase 11–deficient mice have not yet been studied in kidney diseases, including AKI; however, there are in vitro data pointing to this direction.145 Pyroptosis may be targeted by caspase inhibitors or cytokine response modifier A in the case of caspase 1.152

Ferroptosis—Iron-Dependent Necrosis

While searching for novel ways to kill tumor cells, Stockwell and colleagues153 identified a compound named erastin that induces necrotic cell death in highly resistant RAS-transformed cancer cells. Following this path, the previously unrecognized pathway of regulated necrosis turned out to be dependent on iron and was found to involve glutathione metabolism. A plasma membrane Cys/Glu exchanger (termed system Xc-minus) was identified to fuel cells with cysteine, which enables glutathione synthesis required for the reactive oxygen species–eliminating action of glutathione peroxidase 4.154 This enzyme removes H2O2 to prevent intracellular lipid peroxidation, which might directly affect, among others, lysosomal membranes and lead to lysosomal membrane permeabilization. With the detection of these molecular events, ferroptosis turned out to be a druggable pathway of regulated necrosis through the interference with the small molecule ferrostatin-1.155 With respect to kidney tubular cells, first results from kidney tubular cell lines treated with tert-butylhydroperoxide116 and freshly isolated tubules challenged with iron and hydroxyquinoline in the presence of ferrostatin-1 strongly increased cellular survival.156 Additional light has been shed on the role of iron in the pathophysiology of AKI from experiments using proximal tubular cell–specific ferritin heavy chain–deficient mice, which were shown to be sensitive to cisplatin-induced AKI and rhabdomyolysis-induced AKI.157 In addition, renal cell carcinomas were by far the most sensitive in a panel of 60 cancer cell lines from eight tissues tested with erastin.154 Therefore, ferroptosis is one of the promising therapeutic targets, especially in diseases dominated by kidney tubular necrosis,90,158 like ischemic, cisplatin nephrotoxic, and rhabdomyolysis-induced AKI.159 In some of these models, iron chelators have been investigated long before the detection of ferroptosis, but those compounds, such as desferoxamine, never made it into the clinical routine, despite considerable effects in ex vivo experiments with kidney tubules. It will, therefore, be of importance to re-evaluate renal data generated with desferoxamine in light of the molecular understanding of ferroptosis.

Relationship between Apoptosis and Regulated Necrosis

As discussed above, apoptosis and regulated necrosis are characterized by distinguished morphologic, cell biologic, and biochemical features. However, these two forms of regulated cell death are not mutually exclusive, and in many pathologic conditions, including AKI, apoptosis and necrosis coexist. It remains unclear as to what determines if a given cell will die by apoptosis or necrosis.

Apoptosis has been discussed to cause secondary necrosis. However, apoptotic cells may break down their plasma membrane during prolonged injury, displaying a necrotic morphology in vitro. In vivo, apoptotic cells and their debris are thought to be rapidly removed by phagocytic cells.160–163 However, traditional apoptotic signaling, when intercepted, may be diverted to necrosis. This result is well exemplified by necroptosis, in which death receptors are activated but caspase 8 is blocked by pharmacologic or viral inhibition,89,90 resulting in RIPK3-mediated phosphorylation of MLKL and necroptosis.

Apoptosis and regulated necrosis may also interact at various molecular and cellular levels. Clearly, as presented above, both forms of cell death involve pathologic changes in mitochondria. Moreover, Bax is known as a classic proapoptotic Bcl-2 protein that permeabilizes mitochondrial membrane to release apoptotic factors for intrinsic apoptosis. However, Bax has recently been implicated in the regulation of MPT-related necrosis by affecting mitochondrial dynamics.164 In AKI, the involvement of Bax in necrosis may depend on experimental models. Although Bax-null mice showed less tubular apoptosis and necrosis in cisplatin nephrotoxic AKI,65 Bax ablation only has significant effects on tubular apoptosis in ischemia AKI.39 Recent work also showed that RIPK3, the key player in necroptosis, is capable of promoting apoptosis when the kinase function of RIPK3 is lost in vivo165 or in complex in vitro settings, in which cellular inhibitors of apoptosis or the kinase TAK1 are inhibited.166,167 Following this thought, the effectiveness of RIPK3 kinase inhibitors seems to depend on the interaction between RIPK1 and RIPK3 through their RHIM domains.102 Although these interactions between apoptosis and necroptosis have been worked out in detail, very limited data are available on the interaction between apoptosis and other pathways of regulated necrosis, especially pyroptosis, which is hard to investigate because of the limited specificity of caspase inhibitors168 and the dependency of both of these pathways on caspases.90 It is important to understand the complex interplay of the pathways of regulated cell death, especially with the therapeutic idea to target these pathways.

In AKI, very limited information is available on functional or morphologic consequences of interference with apoptosis on other pathways of regulated cell death or vice versa.115 Moreover, the relationship between various forms of cell death in AKI remains to be examined. However, regardless the etiology, AKI is known to involve mixed forms of regulated cell death, and, as presented above, suppression of one form of cell death may have significant renoprotective effects, which nonetheless, are mostly incomplete. The contributions of different forms of cell death in AKI also depend on the nature (ischemic, nephrotoxic, or septic AKI) and severity of the injury. It is important to understand the relative contributions and the potential redundancy of the cell-death pathways to guide the therapeutic strategies for AKI therapy as well as consider the obvious immunologic consequences on the basis of the release of DAMPs from necrotic cell death.169

Targeting Renal Cell Death for AKI Therapy

To date, >1400 PubMed-listed studies on “apoptosis and kidney” or “apoptosis and renal” have been published; unfortunately, no apoptosis-targeting approach has been made into clinical routine in any field (not restricted to the prevention of AKI). Unquestionably, apoptosis is involved in pathologic conditions in kidneys, notably AKI, but whether apoptosis significantly contributes to functional organ failure was recently questioned, because caspase inhibitors (zVAD-fmk, q-VD, and zIETD-fmk) are not efficacious in blocking AKI.27,115 In addition to inhibiting caspases, these inhibitors may affect other cell-death/survival-regulatory pathways, such as autophagy.170 Moreover, at least for death receptor–independent intrinsic apoptosis, inhibition of caspases is at a downstream level of apoptosis, and without blocking upstream apoptotic events, such as those at mitochondria, the viability of renal tubular cells is ultimately lost. In this regard, intrinsic apoptosis is not completely prevented in the presence of caspase inhibitors, like q-VD,171 which raises important questions as to how to target apoptosis for the prevention and treatment of AKI. It is noteworthy that, in AKI, apoptosis does not occur immediately or at one time point; rather, it persists in kidney tissues for days to weeks after injury. For example, in ischemic AKI in mice, tubular apoptosis starts a few hours after reperfusion, reaches the maximal level at 24–48 hours, and lasts for days. Thus, apoptosis, like regulated necrosis, is a continuous process in the disease condition. Accordingly, apoptosis is detected in a relatively low percentage of tubular cells in a snapshot fashion or at any given time points. Nonetheless, the cumulative number of apoptotic cells may become remarkable. In most clinical settings of AKI, patients have passed the initial injury phase; if tubular apoptosis was still occurring at the time of diagnosis, there would be a chance for apoptosis-targeting therapy to prevent additional deterioration of tissue and renal function and time for kidney repair. Additional in vivo investigations with techniques, such as intravital microscopy, may gain insights into the dynamics of apoptosis in AKI, and, more importantly, upstream apoptotic events should be targeted for effective therapy.

Obviously, as outlined in detail above, apoptosis is clearly involved in several pathologic conditions in the kidney, but significant prevention of the primary pathology seen in most preclinical conditions of AKI, necrosis, and functional markers of AKI has not been reproducibly reported through the addition of inhibitors of apoptosis. This finding is in line with the low levels of detection of cleaved caspase 3 in lysates taken from injured kidneys and rarely cleaved caspase 3–positive cells in immunohistochemistry. When it was realized in 2005 that regulated necrosis might serve as a therapeutic target by the identification of Nec-1,172 high hopes were raised for necroptosis-targeting strategies. It was, therefore, disappointing to realize that Nec-1 could only partially protect from ischemic AKI115 and that other pathways might be of importance other than necroptosis. Consequently, because combination therapy seems to be more effective,27 the protection is still incomplete, leaving significant histologic damage and DAMP release. Additional combinations may be useful (e.g., the addition of ferroptosis inhibitor), but it must be kept in mind that the translation of such results into clinical trials is highly problematic; control groups are required for any single- and double-therapeutic strategy, and support of such studies might become long-winded in the absence of strong, convincing preclinical evidence. In addition, for necroptosis, it is understood that plasma membrane rupture occurs as early as 20 minutes after RIPK3 dimerization,91 and application of Nec-1 30 minutes after the beginning of reperfusion has no detectable protective effect.115 Therefore, targeting regulated necrosis may be limited to such disorders in which AKI may be anticipated, like heart surgery–associated AKI, contrast-induced AKI, or kidney transplantation.

In conclusion, tubular apoptosis has been shown unequivocally in various types of AKI, including in diseased human kidneys, but despite 20 years of intensive research, an apoptosis-targeting strategy has not found its way into clinical routine. Recent work has further implicated different forms of regulated necrosis in AKI. Although significant advances have been made in the understanding of the cellular and molecular basis of cell death, targeting of signaling pathways of regulated necrosis for therapy has not yet been investigated in other than promising preclinical settings. Strategically, it is clear now that specific therapeutics have to block upstream events of cell death. In this regard, mitochondria, the converging point of cellular injury and death, may be a promising target of therapy, but mitochondria are not involved in some pathways of regulated necrosis, such as necroptosis, which are clearly relevant in AKI. Therefore, in view of the many subroutines of cell death in AKI, it is necessary to consider combination therapies that block multiple pathways of regulated cell death simultaneously or at different time points to ensure cell survival and renal function.

Disclosures

None.

Acknowledgments

The study was supported, in part, by National Natural Science Foundation of China Grant 81370791 and grants from the National Basic Research Program of China 973 Program 2012CB517601, the National Institutes of Health, and the Department of Veterans Administration. A.L. received support from Novartis, Pfizer, Fresenius, and the Else Kröner-Fresenius Stiftung.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • Copyright © 2014 by the American Society of Nephrology

References

  1. ↵
    1. Lameire NH,
    2. Bagga A,
    3. Cruz D,
    4. De Maeseneer J,
    5. Endre Z,
    6. Kellum JA,
    7. Liu KD,
    8. Mehta RL,
    9. Pannu N,
    10. Van Biesen W,
    11. Vanholder R
    : Acute kidney injury: An increasing global concern. Lancet 382: 170–179, 2013pmid:23727171
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hsu RK,
    2. McCulloch CE,
    3. Dudley RA,
    4. Lo LJ,
    5. Hsu CY
    : Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 24: 37–42, 2013pmid:23222124
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hsu CY
    : Yes, AKI truly leads to CKD. J Am Soc Nephrol 23: 967–969, 2012pmid:22499588
    OpenUrlFREE Full Text
  4. ↵
    1. Faubel S,
    2. Chawla LS,
    3. Chertow GM,
    4. Goldstein SL,
    5. Jaber BL,
    6. Liu KD,
    7. Acute Kidney Injury Advisory Group of the American Society of Nephrology
    : Ongoing clinical trials in AKI. Clin J Am Soc Nephrol 7: 861–873, 2012pmid:22442183
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Bonventre JV,
    2. Yang L
    : Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121: 4210–4221, 2011pmid:22045571
    OpenUrlCrossRefPubMed
    1. Kinsey GR,
    2. Sharma R,
    3. Okusa MD
    : Regulatory T cells in AKI. J Am Soc Nephrol 24: 1720–1726, 2013pmid:24136922
    OpenUrlAbstract/FREE Full Text
    1. Sharfuddin AA,
    2. Molitoris BA
    : Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 7: 189–200, 2011pmid:21364518
    OpenUrlCrossRefPubMed
  6. ↵
    1. Zarjou A,
    2. Agarwal A
    : Sepsis and acute kidney injury. J Am Soc Nephrol 22: 999–1006, 2011pmid:21566052
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ratliff BB,
    2. Rabadi MM,
    3. Vasko R,
    4. Yasuda K,
    5. Goligorsky MS
    : Messengers without borders: Mediators of systemic inflammatory response in AKI. J Am Soc Nephrol 24: 529–536, 2013pmid:23349311
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Schumer M,
    2. Colombel MC,
    3. Sawczuk IS,
    4. Gobé G,
    5. Connor J,
    6. O’Toole KM,
    7. Olsson CA,
    8. Wise GJ,
    9. Buttyan R
    : Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. Am J Pathol 140: 831–838, 1992pmid:1562048
    OpenUrlPubMed
    1. Kelly KJ,
    2. Plotkin Z,
    3. Vulgamott SL,
    4. Dagher PC
    : P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: Protective role of a p53 inhibitor. J Am Soc Nephrol 14: 128–138, 2003pmid:12506145
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Kelly KJ,
    2. Plotkin Z,
    3. Dagher PC
    : Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury. J Clin Invest 108: 1291–1298, 2001pmid:11696573
    OpenUrlCrossRefPubMed
  10. ↵
    1. Basnakian AG,
    2. Ueda N,
    3. Kaushal GP,
    4. Mikhailova MV,
    5. Shah SV
    : DNase I-like endonuclease in rat kidney cortex that is activated during ischemia/reperfusion injury. J Am Soc Nephrol 13: 1000–1007, 2002pmid:11912259
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kaushal GP,
    2. Singh AB,
    3. Shah SV
    : Identification of gene family of caspases in rat kidney and altered expression in ischemia-reperfusion injury. Am J Physiol 274: F587–F595, 1998pmid:9530276
    OpenUrlPubMed
    1. Gobé G,
    2. Zhang XJ,
    3. Willgoss DA,
    4. Schoch E,
    5. Hogg NA,
    6. Endre ZH
    : Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol 11: 454–467, 2000pmid:10703669
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Basile DP,
    2. Liapis H,
    3. Hammerman MR
    : Expression of bcl-2 and bax in regenerating rat renal tubules following ischemic injury. Am J Physiol 272: F640–F647, 1997pmid:9176375
    OpenUrlPubMed
  13. ↵
    1. Miller RP,
    2. Tadagavadi RK,
    3. Ramesh G,
    4. Reeves WB
    : Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2: 2490–2518, 2010pmid:22069563
    OpenUrlCrossRefPubMed
  14. ↵
    1. Pabla N,
    2. Dong Z
    : Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 73: 994–1007, 2008pmid:18272962
    OpenUrlCrossRefPubMed
  15. ↵
    1. Li S,
    2. Basnakian A,
    3. Bhatt R,
    4. Megyesi J,
    5. Gokden N,
    6. Shah SV,
    7. Portilla D
    : PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 287: F990–F998, 2004pmid:15280156
    OpenUrlCrossRefPubMed
    1. Liu H,
    2. Baliga R
    : Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 63: 1687–1696, 2003pmid:12675844
    OpenUrlCrossRefPubMed
    1. Pabla N,
    2. Dong G,
    3. Jiang M,
    4. Huang S,
    5. Kumar MV,
    6. Messing RO,
    7. Dong Z
    : Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 121: 2709–2722, 2011pmid:21633170
    OpenUrlCrossRefPubMed
    1. Ramesh G,
    2. Reeves WB
    : p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289: F166–F174, 2005pmid:15701814
    OpenUrlCrossRefPubMed
    1. Sheikh-Hamad D,
    2. Cacini W,
    3. Buckley AR,
    4. Isaac J,
    5. Truong LD,
    6. Tsao CC,
    7. Kishore BK
    : Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Arch Toxicol 78: 147–155, 2004pmid:14551673
    OpenUrlCrossRefPubMed
  16. ↵
    1. Shiraishi F,
    2. Curtis LM,
    3. Truong L,
    4. Poss K,
    5. Visner GA,
    6. Madsen K,
    7. Nick HS,
    8. Agarwal A
    : Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 278: F726–F736, 2000pmid:10807584
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lerolle N,
    2. Nochy D,
    3. Guérot E,
    4. Bruneval P,
    5. Fagon JY,
    6. Diehl JL,
    7. Hill G
    : Histopathology of septic shock induced acute kidney injury: Apoptosis and leukocytic infiltration. Intensive Care Med 36: 471–478, 2010pmid:19924395
    OpenUrlCrossRefPubMed
  18. ↵
    1. Havasi A,
    2. Borkan SC
    : Apoptosis and acute kidney injury. Kidney Int 80: 29–40, 2011pmid:21562469
    OpenUrlCrossRefPubMed
  19. ↵
    1. Linkermann A,
    2. Bräsen JH,
    3. Darding M,
    4. Jin MK,
    5. Sanz AB,
    6. Heller JO,
    7. De Zen F,
    8. Weinlich R,
    9. Ortiz A,
    10. Walczak H,
    11. Weinberg JM,
    12. Green DR,
    13. Kunzendorf U,
    14. Krautwald S
    : Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci U S A 110: 12024–12029, 2013pmid:23818611
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Wang J,
    2. Wei Q,
    3. Wang CY,
    4. Hill WD,
    5. Hess DC,
    6. Dong Z
    : Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279: 19948–19954, 2004pmid:15004018
    OpenUrlAbstract/FREE Full Text
    1. Wei Q,
    2. Yin XM,
    3. Wang MH,
    4. Dong Z
    : Bid deficiency ameliorates ischemic renal failure and delays animal death in C57BL/6 mice. Am J Physiol Renal Physiol 290: F35–F42, 2006pmid:16106037
    OpenUrlCrossRefPubMed
    1. Wei Q,
    2. Wang MH,
    3. Dong Z
    : Differential gender differences in ischemic and nephrotoxic acute renal failure. Am J Nephrol 25: 491–499, 2005pmid:16155358
    OpenUrlCrossRefPubMed
    1. Jiang M,
    2. Wei Q,
    3. Wang J,
    4. Du Q,
    5. Yu J,
    6. Zhang L,
    7. Dong Z
    : Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056–4066, 2006pmid:16491117
    OpenUrlCrossRefPubMed
    1. Thakar CV,
    2. Zahedi K,
    3. Revelo MP,
    4. Wang Z,
    5. Burnham CE,
    6. Barone S,
    7. Bevans S,
    8. Lentsch AB,
    9. Rabb H,
    10. Soleimani M
    : Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 115: 3451–3459, 2005pmid:16294224
    OpenUrlCrossRefPubMed
  21. ↵
    1. Tanaka T,
    2. Nangaku M,
    3. Miyata T,
    4. Inagi R,
    5. Ohse T,
    6. Ingelfinger JR,
    7. Fujita T
    : Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 15: 2320–2333, 2004pmid:15339981
    OpenUrlAbstract/FREE Full Text
    1. Sharples EJ,
    2. Patel N,
    3. Brown P,
    4. Stewart K,
    5. Mota-Philipe H,
    6. Sheaff M,
    7. Kieswich J,
    8. Allen D,
    9. Harwood S,
    10. Raftery M,
    11. Thiemermann C,
    12. Yaqoob MM
    : Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115–2124, 2004pmid:15284297
    OpenUrlAbstract/FREE Full Text
    1. Lee HT,
    2. Gallos G,
    3. Nasr SH,
    4. Emala CW
    : A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 15: 102–111, 2004pmid:14694162
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Oliver JA,
    2. Maarouf O,
    3. Cheema FH,
    4. Martens TP,
    5. Al-Awqati Q
    : The renal papilla is a niche for adult kidney stem cells. J Clin Invest 114: 795–804, 2004pmid:15372103
    OpenUrlCrossRefPubMed
  23. ↵
    1. Kelly KJ,
    2. Sutton TA,
    3. Weathered N,
    4. Ray N,
    5. Caldwell EJ,
    6. Plotkin Z,
    7. Dagher PC
    : Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 287: F760–F766, 2004pmid:15172883
    OpenUrlCrossRefPubMed
  24. ↵
    1. Linkermann A,
    2. Kunzendorf U,
    3. Krautwald S
    : The authors reply. Kidney Int 83: 531, 2013pmid:23446258
    OpenUrlPubMed
  25. ↵
    1. Wei Q,
    2. Dong G,
    3. Chen JK,
    4. Ramesh G,
    5. Dong Z
    : Bax and Bak have critical roles in ischemic acute kidney injury in global and proximal tubule-specific knockout mouse models. Kidney Int 84: 138–148, 2013pmid:23466994
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ashkenazi A,
    2. Dixit VM
    : Death receptors: Signaling and modulation. Science 281: 1305–1308, 1998pmid:9721089
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Nakagawa T,
    2. Zhu H,
    3. Morishima N,
    4. Li E,
    5. Xu J,
    6. Yankner BA,
    7. Yuan J
    : Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403: 98–103, 2000pmid:10638761
    OpenUrlCrossRefPubMed
  28. ↵
    1. Lassus P,
    2. Opitz-Araya X,
    3. Lazebnik Y
    : Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297: 1352–1354, 2002pmid:12193789
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Cunningham PN,
    2. Dyanov HM,
    3. Park P,
    4. Wang J,
    5. Newell KA,
    6. Quigg RJ
    : Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 168: 5817–5823, 2002pmid:12023385
    OpenUrlAbstract/FREE Full Text
    1. Knotek M,
    2. Rogachev B,
    3. Wang W,
    4. Ecder T,
    5. Melnikov V,
    6. Gengaro PE,
    7. Esson M,
    8. Edelstein CL,
    9. Dinarello CA,
    10. Schrier RW
    : Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59: 2243–2249, 2001pmid:11380827
    OpenUrlCrossRefPubMed
  30. ↵
    1. Ortiz A,
    2. Lorz C,
    3. Egido J
    : The Fas ligand/Fas system in renal injury. Nephrol Dial Transplant 14: 1831–1834, 1999pmid:10462254
    OpenUrlCrossRefPubMed
  31. ↵
    1. Ramesh G,
    2. Reeves WB
    : Inflammatory cytokines in acute renal failure. Kidney Int Suppl 91: S56–S61, 2004pmid:15461705
    OpenUrlPubMed
  32. ↵
    1. Seth R,
    2. Yang C,
    3. Kaushal V,
    4. Shah SV,
    5. Kaushal GP
    : p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280: 31230–31239, 2005pmid:15983031
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Liu H,
    2. Baliga R
    : Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol 16: 1985–1992, 2005pmid:15901768
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Saikumar P,
    2. Dong Z,
    3. Patel Y,
    4. Hall K,
    5. Hopfer U,
    6. Weinberg JM,
    7. Venkatachalam MA
    : Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17: 3401–3415, 1998pmid:10030664
    OpenUrlCrossRefPubMed
    1. Mikhailov V,
    2. Mikhailova M,
    3. Pulkrabek DJ,
    4. Dong Z,
    5. Venkatachalam MA,
    6. Saikumar P
    : Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J Biol Chem 276: 18361–18374, 2001pmid:11279112
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Mikhailov V,
    2. Mikhailova M,
    3. Degenhardt K,
    4. Venkatachalam MA,
    5. White E,
    6. Saikumar P
    : Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J Biol Chem 278: 5367–5376, 2003pmid:12454021
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Qiao X,
    2. Chen X,
    3. Wu D,
    4. Ding R,
    5. Wang J,
    6. Hong Q,
    7. Shi S,
    8. Li J,
    9. Xie Y,
    10. Lu Y,
    11. Wang Z
    : Mitochondrial pathway is responsible for aging-related increase of tubular cell apoptosis in renal ischemia/reperfusion injury. J Gerontol A Biol Sci Med Sci 60: 830–839, 2005pmid:16079204
    OpenUrlCrossRefPubMed
  37. ↵
    1. Wolfs TG,
    2. de Vries B,
    3. Walter SJ,
    4. Peutz-Kootstra CJ,
    5. van Heurn LW,
    6. Oosterhof GO,
    7. Buurman WA
    : Apoptotic cell death is initiated during normothermic ischemia in human kidneys. Am J Transplant 5: 68–75, 2005pmid:15636613
    OpenUrlCrossRefPubMed
  38. ↵
    1. Castaneda MP,
    2. Swiatecka-Urban A,
    3. Mitsnefes MM,
    4. Feuerstein D,
    5. Kaskel FJ,
    6. Tellis V,
    7. Devarajan P
    : Activation of mitochondrial apoptotic pathways in human renal allografts after ischemiareperfusion injury. Transplantation 76: 50–54, 2003pmid:12865785
    OpenUrlCrossRefPubMed
  39. ↵
    1. Luo X,
    2. Budihardjo I,
    3. Zou H,
    4. Slaughter C,
    5. Wang X
    : Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481–490, 1998pmid:9727491
    OpenUrlCrossRefPubMed
  40. ↵
    1. Li H,
    2. Zhu H,
    3. Xu CJ,
    4. Yuan J
    : Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–501, 1998pmid:9727492
    OpenUrlCrossRefPubMed
  41. ↵
    1. Ruiz-Vela A,
    2. Opferman JT,
    3. Cheng EH,
    4. Korsmeyer SJ
    : Proapoptotic BAX and BAK control multiple initiator caspases. EMBO Rep 6: 379–385, 2005pmid:15776018
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Gao Z,
    2. Shao Y,
    3. Jiang X
    : Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J Biol Chem 280: 38271–38275, 2005pmid:16172118
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Martinou JC,
    2. Green DR
    : Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63–67, 2001pmid:11413467
    OpenUrlCrossRefPubMed
  44. ↵
    1. Kroemer G,
    2. Reed JC
    : Mitochondrial control of cell death. Nat Med 6: 513–519, 2000pmid:10802706
    OpenUrlCrossRefPubMed
  45. ↵
    1. Youle RJ,
    2. Strasser A
    : The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47–59, 2008pmid:18097445
    OpenUrlCrossRefPubMed
    1. Danial NN,
    2. Korsmeyer SJ
    : Cell death: Critical control points. Cell 116: 205–219, 2004pmid:14744432
    OpenUrlCrossRefPubMed
  46. ↵
    1. Adams JM,
    2. Cory S
    : The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322–1326, 1998pmid:9735050
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Wei MC,
    2. Zong WX,
    3. Cheng EH,
    4. Lindsten T,
    5. Panoutsakopoulou V,
    6. Ross AJ,
    7. Roth KA,
    8. MacGregor GR,
    9. Thompson CB,
    10. Korsmeyer SJ
    : Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292: 727–730, 2001pmid:11326099
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Wei Q,
    2. Dong G,
    3. Franklin J,
    4. Dong Z
    : The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72: 53–62, 2007pmid:17410096
    OpenUrlCrossRefPubMed
  49. ↵
    1. Takahashi Y,
    2. Karbowski M,
    3. Yamaguchi H,
    4. Kazi A,
    5. Wu J,
    6. Sebti SM,
    7. Youle RJ,
    8. Wang HG
    : Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol 25: 9369–9382, 2005pmid:16227588
    OpenUrlAbstract/FREE Full Text
    1. Sawada M,
    2. Sun W,
    3. Hayes P,
    4. Leskov K,
    5. Boothman DA,
    6. Matsuyama S
    : Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5: 320–329, 2003pmid:12652308
    OpenUrlCrossRefPubMed
    1. Yi X,
    2. Yin XM,
    3. Dong Z
    : Inhibition of Bid-induced apoptosis by Bcl-2. tBid insertion, Bax translocation, and Bax/Bak oligomerization suppressed. J Biol Chem 278: 16992–16999, 2003pmid:12624108
    OpenUrlAbstract/FREE Full Text
    1. Nomura M,
    2. Shimizu S,
    3. Sugiyama T,
    4. Narita M,
    5. Ito T,
    6. Matsuda H,
    7. Tsujimoto Y
    : 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 278: 2058–2065, 2003pmid:12426317
    OpenUrlAbstract/FREE Full Text
    1. Guo B,
    2. Zhai D,
    3. Cabezas E,
    4. Welsh K,
    5. Nouraini S,
    6. Satterthwait AC,
    7. Reed JC
    : Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423: 456–461, 2003pmid:12732850
    OpenUrlCrossRefPubMed
    1. Eskes R,
    2. Desagher S,
    3. Antonsson B,
    4. Martinou JC
    : Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929–935, 2000pmid:10629050
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Chipuk JE,
    2. Kuwana T,
    3. Bouchier-Hayes L,
    4. Droin NM,
    5. Newmeyer DD,
    6. Schuler M,
    7. Green DR
    : Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303: 1010–1014, 2004pmid:14963330
    OpenUrlAbstract/FREE Full Text
  51. ↵
    1. Wang Z,
    2. Gall JM,
    3. Bonegio R,
    4. Havasi A,
    5. Illanes K,
    6. Schwartz JH,
    7. Borkan SC
    : Nucleophosmin, a critical Bax cofactor in ischemia-induced cell death. Mol Cell Biol 33: 1916–1924, 2013pmid:23459946
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Youle RJ,
    2. van der Bliek AM
    : Mitochondrial fission, fusion, and stress. Science 337: 1062–1065, 2012pmid:22936770
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Chan DC
    : Fusion and fission: Interlinked processes critical for mitochondrial health. Annu Rev Genet 46: 265–287, 2012pmid:22934639
    OpenUrlCrossRefPubMed
  54. ↵
    1. Frank S,
    2. Gaume B,
    3. Bergmann-Leitner ES,
    4. Leitner WW,
    5. Robert EG,
    6. Catez F,
    7. Smith CL,
    8. Youle RJ
    : The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 1: 515–525, 2001pmid:11703942
    OpenUrlCrossRefPubMed
  55. ↵
    1. Brooks C,
    2. Wei Q,
    3. Cho SG,
    4. Dong Z
    : Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 119: 1275–1285, 2009pmid:19349686
    OpenUrlCrossRefPubMed
  56. ↵
    1. Grohm J,
    2. Kim SW,
    3. Mamrak U,
    4. Tobaben S,
    5. Cassidy-Stone A,
    6. Nunnari J,
    7. Plesnila N,
    8. Culmsee C
    : Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ 19: 1446–1458, 2012pmid:22388349
    OpenUrlCrossRefPubMed
  57. ↵
    1. Ong SB,
    2. Subrayan S,
    3. Lim SY,
    4. Yellon DM,
    5. Davidson SM,
    6. Hausenloy DJ
    : Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121: 2012–2022, 2010pmid:20421521
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Cho SG,
    2. Du Q,
    3. Huang S,
    4. Dong Z
    : Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. Am J Physiol Renal Physiol 299: F199–F206, 2010pmid:20410216
    OpenUrlCrossRefPubMed
  59. ↵
    1. Brooks C,
    2. Wei Q,
    3. Feng L,
    4. Dong G,
    5. Tao Y,
    6. Mei L,
    7. Xie ZJ,
    8. Dong Z
    : Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci U S A 104: 11649–11654, 2007pmid:17606912
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Waxman AB,
    2. Kolliputi N
    : IL-6 protects against hyperoxia-induced mitochondrial damage via Bcl-2-induced Bak interactions with mitofusins. Am J Respir Cell Mol Biol 41: 385–396, 2009pmid:19168699
    OpenUrlCrossRefPubMed
  61. ↵
    1. Brooks C,
    2. Cho SG,
    3. Wang CY,
    4. Yang T,
    5. Dong Z
    : Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis. Am J Physiol Cell Physiol 300: C447–C455, 2011pmid:21160028
    OpenUrlCrossRefPubMed
  62. ↵
    1. Zhan M,
    2. Brooks C,
    3. Liu F,
    4. Sun L,
    5. Dong Z
    : Mitochondrial dynamics: Regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int 83: 568–581, 2013pmid:23325082
    OpenUrlCrossRefPubMed
  63. ↵
    1. Wang W,
    2. Wang Y,
    3. Long J,
    4. Wang J,
    5. Haudek SB,
    6. Overbeek P,
    7. Chang BH,
    8. Schumacker PT,
    9. Danesh FR
    : Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab 15: 186–200, 2012pmid:22326220
    OpenUrlCrossRefPubMed
  64. ↵
    1. Kaczmarek A,
    2. Vandenabeele P,
    3. Krysko DV
    : Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity 38: 209–223, 2013pmid:23438821
    OpenUrlCrossRefPubMed
  65. ↵
    1. Kono H,
    2. Rock KL
    : How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279–289, 2008pmid:18340345
    OpenUrlCrossRefPubMed
  66. ↵
    1. Linkermann A,
    2. Hackl MJ,
    3. Kunzendorf U,
    4. Walczak H,
    5. Krautwald S,
    6. Jevnikar AM
    : Necroptosis in immunity and ischemia-reperfusion injury. Am J Transplant 13: 2797–2804, 2013pmid:24103029
    OpenUrlCrossRefPubMed
  67. ↵
    1. Galluzzi L,
    2. Kepp O,
    3. Krautwald S,
    4. Kroemer G,
    5. Linkermann A
    : Molecular mechanisms of regulated necrosis [published online ahead of print February 26, 2014]. Semin Cell Dev Biol 10.1016/j.semcdb.2014.02.006pmid:24582829
    OpenUrlCrossRefPubMed
  68. ↵
    1. Vanden Berghe T,
    2. Linkermann A,
    3. Jouan-Lanhouet S,
    4. Walczak H,
    5. Vandenabeele P
    : Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 15: 135–147, 2014pmid:24452471
    OpenUrlCrossRefPubMed
  69. ↵
    1. Tait SW,
    2. Oberst A,
    3. Quarato G,
    4. Milasta S,
    5. Haller M,
    6. Wang R,
    7. Karvela M,
    8. Ichim G,
    9. Yatim N,
    10. Albert ML,
    11. Kidd G,
    12. Wakefield R,
    13. Frase S,
    14. Krautwald S,
    15. Linkermann A,
    16. Green DR
    : Widespread mitochondrial depletion via mitophagy does not compromise necroptosis. Cell Reports 5: 878–885, 2013pmid:24268776
    OpenUrlCrossRefPubMed
  70. ↵
    1. Kaiser WJ,
    2. Upton JW,
    3. Long AB,
    4. Livingston-Rosanoff D,
    5. Daley-Bauer LP,
    6. Hakem R,
    7. Caspary T,
    8. Mocarski ES
    : RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368–372, 2011pmid:21368762
    OpenUrlCrossRefPubMed
  71. ↵
    1. Oberst A,
    2. Dillon CP,
    3. Weinlich R,
    4. McCormick LL,
    5. Fitzgerald P,
    6. Pop C,
    7. Hakem R,
    8. Salvesen GS,
    9. Green DR
    : Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471: 363–367, 2011pmid:21368763
    OpenUrlCrossRefPubMed
  72. ↵
    1. Newton K,
    2. Sun X,
    3. Dixit VM
    : Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol 24: 1464–1469, 2004pmid:14749364
    OpenUrlAbstract/FREE Full Text
  73. ↵
    1. Oberst A,
    2. Green DR
    : It cuts both ways: Reconciling the dual roles of caspase 8 in cell death and survival. Nat Rev Mol Cell Biol 12: 757–763, 2011pmid:22016059
    OpenUrlCrossRefPubMed
  74. ↵
    1. Green DR
    : Apoptotic pathways: Ten minutes to dead. Cell 121: 671–674, 2005pmid:15935754
    OpenUrlCrossRefPubMed
  75. ↵
    1. Krammer PH,
    2. Arnold R,
    3. Lavrik IN
    : Life and death in peripheral T cells. Nat Rev Immunol 7: 532–542, 2007pmid:17589543
    OpenUrlCrossRefPubMed
  76. ↵
    1. Kang TB,
    2. Yang SH,
    3. Toth B,
    4. Kovalenko A,
    5. Wallach D
    : Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38: 27–40, 2013pmid:23260196
    OpenUrlCrossRefPubMed
  77. ↵
    1. Linkermann A,
    2. Green DR
    : Necroptosis. N Engl J Med 370: 455–465, 2014pmid:24476434
    OpenUrlCrossRefPubMed
  78. ↵
    1. Holler N,
    2. Zaru R,
    3. Micheau O,
    4. Thome M,
    5. Attinger A,
    6. Valitutti S,
    7. Bodmer JL,
    8. Schneider P,
    9. Seed B,
    10. Tschopp J
    : Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1: 489–495, 2000pmid:11101870
    OpenUrlCrossRefPubMed
  79. ↵
    1. Vercammen D,
    2. Beyaert R,
    3. Denecker G,
    4. Goossens V,
    5. Van Loo G,
    6. Declercq W,
    7. Grooten J,
    8. Fiers W,
    9. Vandenabeele P
    : Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 187: 1477–1485, 1998pmid:9565639
    OpenUrlAbstract/FREE Full Text
  80. ↵
    1. Kaiser WJ,
    2. Sridharan H,
    3. Huang C,
    4. Mandal P,
    5. Upton JW,
    6. Gough PJ,
    7. Sehon CA,
    8. Marquis RW,
    9. Bertin J,
    10. Mocarski ES
    : Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 288: 31268–31279, 2013pmid:24019532
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Thapa RJ,
    2. Basagoudanavar SH,
    3. Nogusa S,
    4. Irrinki K,
    5. Mallilankaraman K,
    6. Slifker MJ,
    7. Beg AA,
    8. Madesh M,
    9. Balachandran S
    : NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol 31: 2934–2946, 2011pmid:21576359
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Thapa RJ,
    2. Nogusa S,
    3. Chen P,
    4. Maki JL,
    5. Lerro A,
    6. Andrake M,
    7. Rall GF,
    8. Degterev A,
    9. Balachandran S
    : Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci U S A 110: E3109–E3118, 2013pmid:23898178
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Upton JW,
    2. Kaiser WJ,
    3. Mocarski ES
    : Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 7: 302–313, 2010pmid:20413098
    OpenUrlCrossRefPubMed
  84. ↵
    1. Upton JW,
    2. Kaiser WJ,
    3. Mocarski ES
    : DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11: 290–297, 2012pmid:22423968
    OpenUrlCrossRefPubMed
  85. ↵
    1. Cho YS,
    2. Challa S,
    3. Moquin D,
    4. Genga R,
    5. Ray TD,
    6. Guildford M,
    7. Chan FK
    : Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137: 1112–1123, 2009pmid:19524513
    OpenUrlCrossRefPubMed
  86. ↵
    1. He S,
    2. Wang L,
    3. Miao L,
    4. Wang T,
    5. Du F,
    6. Zhao L,
    7. Wang X
    : Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137: 1100–1111, 2009pmid:19524512
    OpenUrlCrossRefPubMed
  87. ↵
    1. Zhang DW,
    2. Shao J,
    3. Lin J,
    4. Zhang N,
    5. Lu BJ,
    6. Lin SC,
    7. Dong MQ,
    8. Han J
    : RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325: 332–336, 2009pmid:19498109
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Murphy JM,
    2. Czabotar PE,
    3. Hildebrand JM,
    4. Lucet IS,
    5. Zhang JG,
    6. Alvarez-Diaz S,
    7. Lewis R,
    8. Lalaoui N,
    9. Metcalf D,
    10. Webb AI,
    11. Young SN,
    12. Varghese LN,
    13. Tannahill GM,
    14. Hatchell EC,
    15. Majewski IJ,
    16. Okamoto T,
    17. Dobson RC,
    18. Hilton DJ,
    19. Babon JJ,
    20. Nicola NA,
    21. Strasser A,
    22. Silke J,
    23. Alexander WS
    : The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39: 443–453, 2013pmid:24012422
    OpenUrlCrossRefPubMed
  89. ↵
    1. Sun L,
    2. Wang H,
    3. Wang Z,
    4. He S,
    5. Chen S,
    6. Liao D,
    7. Wang L,
    8. Yan J,
    9. Liu W,
    10. Lei X,
    11. Wang X
    : Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148: 213–227, 2012pmid:22265413
    OpenUrlCrossRefPubMed
  90. ↵
    1. Zhao J,
    2. Jitkaew S,
    3. Cai Z,
    4. Choksi S,
    5. Li Q,
    6. Luo J,
    7. Liu ZG
    : Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A 109: 5322–5327, 2012pmid:22421439
    OpenUrlAbstract/FREE Full Text
  91. ↵
    1. Murphy JM,
    2. Lucet IS,
    3. Hildebrand JM,
    4. Tanzer MC,
    5. Young SN,
    6. Sharma P,
    7. Lessene G,
    8. Alexander WS,
    9. Babon JJ,
    10. Silke J,
    11. Czabotar PE
    : Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. Biochem J 457: 369–377, 2014pmid:24219132
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Wang H,
    2. Sun L,
    3. Su L,
    4. Rizo J,
    5. Liu L,
    6. Wang LF,
    7. Wang FS,
    8. Wang X
    : Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 54: 133–146, 2014pmid:24703947
    OpenUrlCrossRefPubMed
  93. ↵
    1. Linkermann A,
    2. Bräsen JH,
    3. Himmerkus N,
    4. Liu S,
    5. Huber TB,
    6. Kunzendorf U,
    7. Krautwald S
    : Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int 81: 751–761, 2012pmid:22237751
    OpenUrlCrossRefPubMed
  94. ↵
    1. Nowak G,
    2. Soundararajan S,
    3. Mestril R
    : Protein kinase C-α interaction with iHSP70 in mitochondria promotes recovery of mitochondrial function after injury in renal proximal tubular cells. Am J Physiol Renal Physiol 305: F764–F776, 2013pmid:23804450
    OpenUrlCrossRefPubMed
    1. Tristão VR,
    2. Gonçalves PF,
    3. Dalboni MA,
    4. Batista MC,
    5. Durão MS Jr.,
    6. Monte JC
    : Nec-1 protects against nonapoptotic cell death in cisplatin-induced kidney injury. Ren Fail 34: 373–377, 2012pmid:22260305
    OpenUrlCrossRefPubMed
  95. ↵
    1. Zhang L,
    2. Jiang F,
    3. Chen Y,
    4. Luo J,
    5. Liu S,
    6. Zhang B,
    7. Ye Z,
    8. Wang W,
    9. Liang X,
    10. Shi W
    : Necrostatin-1 attenuates ischemia injury induced cell death in rat tubular cell line NRK-52E through decreased Drp1 expression. Int J Mol Sci 14: 24742–24754, 2013pmid:24351845
    OpenUrlCrossRefPubMed
  96. ↵
    1. Daemen MA,
    2. van ’t Veer C,
    3. Denecker G,
    4. Heemskerk VH,
    5. Wolfs TG,
    6. Clauss M,
    7. Vandenabeele P,
    8. Buurman WA
    : Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 104: 541–549, 1999pmid:10487768
    OpenUrlCrossRefPubMed
  97. ↵
    1. Ouyang Z,
    2. Zhu S,
    3. Jin J,
    4. Li J,
    5. Qiu Y,
    6. Huang M,
    7. Huang Z
    : Necroptosis contributes to the cyclosporin A-induced cytotoxicity in NRK-52E cells. Pharmazie 67: 725–732, 2012pmid:22957440
    OpenUrlPubMed
  98. ↵
    1. Linkermann A,
    2. Heller JO,
    3. Prókai A,
    4. Weinberg JM,
    5. De Zen F,
    6. Himmerkus N,
    7. Szabó AJ,
    8. Bräsen JH,
    9. Kunzendorf U,
    10. Krautwald S
    : The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol 24: 1545–1557, 2013pmid:23833261
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Hakroush S,
    2. Cebulla A,
    3. Schaldecker T,
    4. Behr D,
    5. Mundel P,
    6. Weins A
    : Extensive podocyte loss triggers a rapid parietal epithelial cell response [published online ahead of print December 12, 2013]. J Am Soc Nephrolpmid:24335975
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Green DR,
    2. Ferguson T,
    3. Zitvogel L,
    4. Kroemer G
    : Immunogenic and tolerogenic cell death. Nat Rev Immunol 9: 353–363, 2009pmid:19365408
    OpenUrlCrossRefPubMed
  101. ↵
    1. Tait SW,
    2. Green DR
    : Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621–632, 2010pmid:20683470
    OpenUrlCrossRefPubMed
  102. ↵
    1. Kroemer G,
    2. Galluzzi L,
    3. Brenner C
    : Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99–163, 2007pmid:17237344
    OpenUrlCrossRefPubMed
  103. ↵
    1. Kim JS,
    2. He L,
    3. Lemasters JJ
    : Mitochondrial permeability transition: A common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 304: 463–470, 2003pmid:12729580
    OpenUrlCrossRefPubMed
    1. Bernardi P
    : The mitochondrial permeability transition pore: A mystery solved? Front Physiol 4: 95, 2013pmid:23675351
    OpenUrlCrossRefPubMed
  104. ↵
    1. Giorgio V,
    2. von Stockum S,
    3. Antoniel M,
    4. Fabbro A,
    5. Fogolari F,
    6. Forte M,
    7. Glick GD,
    8. Petronilli V,
    9. Zoratti M,
    10. Szabó I,
    11. Lippe G,
    12. Bernardi P
    : Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A 110: 5887–5892, 2013pmid:23530243
    OpenUrlAbstract/FREE Full Text
  105. ↵
    1. Devalaraja-Narashimha K,
    2. Diener AM,
    3. Padanilam BJ
    : Cyclophilin D gene ablation protects mice from ischemic renal injury. Am J Physiol Renal Physiol 297: F749–F759, 2009pmid:19553348
    OpenUrlCrossRefPubMed
  106. ↵
    1. Park JS,
    2. Pasupulati R,
    3. Feldkamp T,
    4. Roeser NF,
    5. Weinberg JM
    : Cyclophilin D and the mitochondrial permeability transition in kidney proximal tubules after hypoxic and ischemic injury. Am J Physiol Renal Physiol 301: F134–F150, 2011pmid:21490135
    OpenUrlCrossRefPubMed
  107. ↵
    1. Baumann K
    : Cell death: Multitasking p53 promotes necrosis. Nat Rev Mol Cell Biol 13: 480–481, 2012pmid:22781904
    OpenUrlCrossRefPubMed
  108. ↵
    1. Vaseva AV,
    2. Marchenko ND,
    3. Ji K,
    4. Tsirka SE,
    5. Holzmann S,
    6. Moll UM
    : p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149: 1536–1548, 2012pmid:22726440
    OpenUrlCrossRefPubMed
  109. ↵
    1. Karch J,
    2. Molkentin JD
    : Is p53 the long-sought molecular trigger for cyclophilin D-regulated mitochondrial permeability transition pore formation and necrosis? Circ Res 111: 1258–1260, 2012pmid:23104876
    OpenUrlFREE Full Text
  110. ↵
    1. Clarke SJ,
    2. McStay GP,
    3. Halestrap AP
    : Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 277: 34793–34799, 2002pmid:12095984
    OpenUrlAbstract/FREE Full Text
    1. Weinberg JM,
    2. Roeser NF,
    3. Davis JA,
    4. Venkatachalam MA
    : Glycine-protected, hypoxic, proximal tubules develop severely compromised energetic function. Kidney Int 52: 140–151, 1997pmid:9211356
    OpenUrlCrossRefPubMed
  111. ↵
    1. Feldkamp T,
    2. Park JS,
    3. Pasupulati R,
    4. Amora D,
    5. Roeser NF,
    6. Venkatachalam MA,
    7. Weinberg JM
    : Regulation of the mitochondrial permeability transition in kidney proximal tubules and its alteration during hypoxia-reoxygenation. Am J Physiol Renal Physiol 297: F1632–F1646, 2009pmid:19741014
    OpenUrlCrossRefPubMed
  112. ↵
    1. Piot C,
    2. Croisille P,
    3. Staat P,
    4. Thibault H,
    5. Rioufol G,
    6. Mewton N,
    7. Elbelghiti R,
    8. Cung TT,
    9. Bonnefoy E,
    10. Angoulvant D,
    11. Macia C,
    12. Raczka F,
    13. Sportouch C,
    14. Gahide G,
    15. Finet G,
    16. André-Fouët X,
    17. Revel D,
    18. Kirkorian G,
    19. Monassier JP,
    20. Derumeaux G,
    21. Ovize M
    : Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473–481, 2008pmid:18669426
    OpenUrlCrossRefPubMed
  113. ↵
    1. Kim J,
    2. Padanilam BJ
    : Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Renal Physiol 301: F450–F459, 2011pmid:21613422
    OpenUrlCrossRefPubMed
  114. ↵
    1. Kim J,
    2. Long KE,
    3. Tang K,
    4. Padanilam BJ
    : Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 82: 193–203, 2012pmid:22437413
    OpenUrlCrossRefPubMed
  115. ↵
    1. Bergsbaken T,
    2. Fink SL,
    3. Cookson BT
    : Pyroptosis: Host cell death and inflammation. Nat Rev Microbiol 7: 99–109, 2009pmid:19148178
    OpenUrlCrossRefPubMed
  116. ↵
    1. Bergsbaken T,
    2. Fink SL,
    3. den Hartigh AB,
    4. Loomis WP,
    5. Cookson BT
    : Coordinated host responses during pyroptosis: Caspase-1-dependent lysosome exocytosis and inflammatory cytokine maturation. J Immunol 187: 2748–2754, 2011pmid:21804020
    OpenUrlAbstract/FREE Full Text
  117. ↵
    1. Doitsh G,
    2. Galloway NL,
    3. Geng X,
    4. Yang Z,
    5. Monroe KM,
    6. Zepeda O,
    7. Hunt PW,
    8. Hatano H,
    9. Sowinski S,
    10. Muñoz-Arias I,
    11. Greene WC
    : Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505: 509–514, 2014pmid:24356306
    OpenUrlCrossRefPubMed
  118. ↵
    1. Adamczak SE,
    2. de Rivero Vaccari JP,
    3. Dale G,
    4. Brand FJ 3rd,
    5. Nonner D,
    6. Bullock MR,
    7. Dahl GP,
    8. Dietrich WD,
    9. Keane RW
    : Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J Cereb Blood Flow Metab 34: 621–629, 2014pmid:24398937
    OpenUrlCrossRefPubMed
  119. ↵
    1. Chung SD,
    2. Lai TY,
    3. Chien CT,
    4. Yu HJ
    : Activating Nrf-2 signaling depresses unilateral ureteral obstruction-evoked mitochondrial stress-related autophagy, apoptosis and pyroptosis in kidney. PLoS ONE 7: e47299, 2012pmid:23071780
    OpenUrlCrossRefPubMed
  120. ↵
    1. Yang JR,
    2. Yao FH,
    3. Zhang JG,
    4. Ji ZY,
    5. Li KL,
    6. Zhan J,
    7. Tong YN,
    8. Lin LR,
    9. He YN
    : Ischemia-reperfusion induces renal tubule pyroptosis via the CHOP-caspase-11 pathway. Am J Physiol Renal Physiol 306: F75–F84, 2014pmid:24133119
    OpenUrlCrossRefPubMed
    1. Lorenz G,
    2. Darisipudi MN,
    3. Anders HJ
    : Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 29: 41–48, 2014pmid:24026244
    OpenUrlCrossRefPubMed
  121. ↵
    1. Krautwald S,
    2. Linkermann A
    : The fire within: Pyroptosis in the kidney. Am J Physiol Renal Physiol 306: F168–F169, 2014pmid:24226525
    OpenUrlCrossRefPubMed
  122. ↵
    1. Case CL,
    2. Shin S,
    3. Roy CR
    : Asc and Ipaf Inflammasomes direct distinct pathways for caspase-1 activation in response to Legionella pneumophila. Infect Immun 77: 1981–1991, 2009pmid:19237518
    OpenUrlAbstract/FREE Full Text
    1. Sauer JD,
    2. Pereyre S,
    3. Archer KA,
    4. Burke TP,
    5. Hanson B,
    6. Lauer P,
    7. Portnoy DA
    : Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity. Proc Natl Acad Sci U S A 108: 12419–12424, 2011pmid:21746921
    OpenUrlAbstract/FREE Full Text
  123. ↵
    1. Miao EA,
    2. Leaf IA,
    3. Treuting PM,
    4. Mao DP,
    5. Dors M,
    6. Sarkar A,
    7. Warren SE,
    8. Wewers MD,
    9. Aderem A
    : Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 11: 1136–1142, 2010pmid:21057511
    OpenUrlCrossRefPubMed
  124. ↵
    1. Kayagaki N,
    2. Warming S,
    3. Lamkanfi M,
    4. Vande Walle L,
    5. Louie S,
    6. Dong J,
    7. Newton K,
    8. Qu Y,
    9. Liu J,
    10. Heldens S,
    11. Zhang J,
    12. Lee WP,
    13. Roose-Girma M,
    14. Dixit VM
    : Non-canonical inflammasome activation targets caspase-11. Nature 479: 117–121, 2011pmid:22002608
    OpenUrlCrossRefPubMed
  125. ↵
    1. Krautwald S,
    2. Ziegler E,
    3. Rölver L,
    4. Linkermann A,
    5. Keyser KA,
    6. Steen P,
    7. Wollert KC,
    8. Korf-Klingebiel M,
    9. Kunzendorf U
    : Effective blockage of both the extrinsic and intrinsic pathways of apoptosis in mice by TAT-crmA. J Biol Chem 285: 19997–20005, 2010pmid:20427266
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Yagoda N,
    2. von Rechenberg M,
    3. Zaganjor E,
    4. Bauer AJ,
    5. Yang WS,
    6. Fridman DJ,
    7. Wolpaw AJ,
    8. Smukste I,
    9. Peltier JM,
    10. Boniface JJ,
    11. Smith R,
    12. Lessnick SL,
    13. Sahasrabudhe S,
    14. Stockwell BR
    : RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447: 864–868, 2007pmid:17568748
    OpenUrlCrossRefPubMed
  127. ↵
    1. Yang WS,
    2. SriRamaratnam R,
    3. Welsch ME,
    4. Shimada K,
    5. Skouta R,
    6. Viswanathan VS,
    7. Cheah JH,
    8. Clemons PA,
    9. Shamji AF,
    10. Clish CB,
    11. Brown LM,
    12. Girotti AW,
    13. Cornish VW,
    14. Schreiber SL,
    15. Stockwell BR
    : Regulation of ferroptotic cancer cell death by GPX4. Cell 156: 317–331, 2014pmid:24439385
    OpenUrlCrossRefPubMed
  128. ↵
    1. Dixon SJ,
    2. Lemberg KM,
    3. Lamprecht MR,
    4. Skouta R,
    5. Zaitsev EM,
    6. Gleason CE,
    7. Patel DN,
    8. Bauer AJ,
    9. Cantley AM,
    10. Yang WS,
    11. Morrison B 3rd,
    12. Stockwell BR
    : Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149: 1060–1072, 2012pmid:22632970
    OpenUrlCrossRefPubMed
  129. ↵
    1. Skouta R,
    2. Dixon SJ,
    3. Wang J,
    4. Dunn DE,
    5. Orman M,
    6. Shimada K,
    7. Rosenberg PA,
    8. Lo DC,
    9. Weinberg JM,
    10. Linkermann A,
    11. Stockwell BR
    : Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc 136: 4551–4556, 2014pmid:24592866
    OpenUrlCrossRefPubMed
  130. ↵
    1. Zarjou A,
    2. Bolisetty S,
    3. Joseph R,
    4. Traylor A,
    5. Apostolov EO,
    6. Arosio P,
    7. Balla J,
    8. Verlander J,
    9. Darshan D,
    10. Kuhn LC,
    11. Agarwal A
    : Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest 123: 4423–4434, 2013pmid:24018561
    OpenUrlCrossRefPubMed
  131. ↵
    1. Dixon SJ,
    2. Stockwell BR
    : The role of iron and reactive oxygen species in cell death. Nat Chem Biol 10: 9–17, 2014pmid:24346035
    OpenUrlCrossRefPubMed
  132. ↵
    1. Fähling M,
    2. Mathia S,
    3. Paliege A,
    4. Koesters R,
    5. Mrowka R,
    6. Peters H,
    7. Persson PB,
    8. Neumayer HH,
    9. Bachmann S,
    10. Rosenberger C
    : Tubular von Hippel-Lindau knockout protects against rhabdomyolysis-induced AKI. J Am Soc Nephrol 24: 1806–1819, 2013pmid:23970125
    OpenUrlAbstract/FREE Full Text
  133. ↵
    1. Poon IK,
    2. Chiu YH,
    3. Armstrong AJ,
    4. Kinchen JM,
    5. Juncadella IJ,
    6. Bayliss DA,
    7. Ravichandran KS
    : Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature 507: 329–334, 2014pmid:24646995
    OpenUrlCrossRefPubMed
    1. Juncadella IJ,
    2. Kadl A,
    3. Sharma AK,
    4. Shim YM,
    5. Hochreiter-Hufford A,
    6. Borish L,
    7. Ravichandran KS
    : Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 493: 547–551, 2013pmid:23235830
    OpenUrlCrossRefPubMed
    1. Elliott MR,
    2. Chekeni FB,
    3. Trampont PC,
    4. Lazarowski ER,
    5. Kadl A,
    6. Walk SF,
    7. Park D,
    8. Woodson RI,
    9. Ostankovich M,
    10. Sharma P,
    11. Lysiak JJ,
    12. Harden TK,
    13. Leitinger N,
    14. Ravichandran KS
    : Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461: 282–286, 2009pmid:19741708
    OpenUrlCrossRefPubMed
  134. ↵
    1. Vanden Berghe T,
    2. Vanlangenakker N,
    3. Parthoens E,
    4. Deckers W,
    5. Devos M,
    6. Festjens N,
    7. Guerin CJ,
    8. Brunk UT,
    9. Declercq W,
    10. Vandenabeele P
    : Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 17: 922–930, 2010
    OpenUrlCrossRefPubMed
  135. ↵
    1. O’Rourke B,
    2. Kitsis RN
    1. Whelan RS,
    2. Konstantinidis K,
    3. Wei AC,
    4. Chen Y,
    5. Reyna DE,
    6. Jha S,
    7. Yang Y,
    8. Calvert JW,
    9. Lindsten T,
    10. Thompson CB,
    11. Crow MT,
    12. Gavathiotis E,
    13. Dorn GW
    2ndO’Rourke B, Kitsis RN: Bax regulates primary necrosis through mitochondrial dynamics. Proc Natl Acad Sci U S A 109: 6566–6571, 2012
    OpenUrlAbstract/FREE Full Text
  136. ↵
    1. Newton K,
    2. Dugger DL,
    3. Wickliffe KE,
    4. Kapoor N,
    5. de Almagro MC,
    6. Vucic D,
    7. Komuves L,
    8. Ferrando RE,
    9. French DM,
    10. Webster J,
    11. Roose-Girma M,
    12. Warming S,
    13. Dixit VM
    : Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 343: 1357–1360, 2014
    OpenUrlAbstract/FREE Full Text
  137. ↵
    1. Dondelinger Y,
    2. Aguileta MA,
    3. Goossens V,
    4. Dubuisson C,
    5. Grootjans S,
    6. Dejardin E,
    7. Vandenabeele P,
    8. Bertrand MJ
    : RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell Death Differ 20: 1381–1392, 2013pmid:23892367
    OpenUrlCrossRefPubMed
  138. ↵
    1. Remijsen Q,
    2. Goossens V,
    3. Grootjans S,
    4. Van den Haute C,
    5. Vanlangenakker N,
    6. Dondelinger Y,
    7. Roelandt R,
    8. Bruggeman I,
    9. Goncalves A,
    10. Bertrand MJ,
    11. Baekelandt V,
    12. Takahashi N,
    13. Berghe TV,
    14. Vandenabeele P
    : Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell Death Dis 5: e1004, 2014pmid:24434512
    OpenUrlCrossRefPubMed
  139. ↵
    1. Garcia-Calvo M,
    2. Peterson EP,
    3. Leiting B,
    4. Ruel R,
    5. Nicholson DW,
    6. Thornberry NA
    : Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273: 32608–32613, 1998pmid:9829999
    OpenUrlAbstract/FREE Full Text
  140. ↵
    1. Anders HJ,
    2. Schaefer L
    : Beyond tissue injury—damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis [published online ahead of print April 24, 2014]. J Am Soc Nephrolpmid:24762401
    OpenUrlAbstract/FREE Full Text
  141. ↵
    1. Herzog C,
    2. Yang C,
    3. Holmes A,
    4. Kaushal GP
    : zVAD-fmk prevents cisplatin-induced cleavage of autophagy proteins but impairs autophagic flux and worsens renal function. Am J Physiol Renal Physiol 303: F1239–F1250, 2012pmid:22896037
    OpenUrlCrossRefPubMed
  142. ↵
    1. Josefsson EC,
    2. Burnett DL,
    3. Lebois M,
    4. Debrincat MA,
    5. White MJ,
    6. Henley KJ,
    7. Lane RM,
    8. Moujalled D,
    9. Preston SP,
    10. O’Reilly LA,
    11. Pellegrini M,
    12. Metcalf D,
    13. Strasser A,
    14. Kile BT
    : Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways. Nat Commun 5: 3455, 2014pmid:24632563
    OpenUrlCrossRefPubMed
  143. ↵
    1. Degterev A,
    2. Huang Z,
    3. Boyce M,
    4. Li Y,
    5. Jagtap P,
    6. Mizushima N,
    7. Cuny GD,
    8. Mitchison TJ,
    9. Moskowitz MA,
    10. Yuan J
    : Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1: 112–119, 2005pmid:16408008
    OpenUrlCrossRefPubMed
  144. ↵
    1. Weinlich R,
    2. Oberst A,
    3. Dillon CP,
    4. Janke LJ,
    5. Milasta S,
    6. Lukens JR,
    7. Rodriguez DA,
    8. Gurung P,
    9. Savage C,
    10. Kanneganti TD,
    11. Green DR
    : Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Reports 5: 340–348, 2013pmid:24095739
    OpenUrlCrossRefPubMed
  145. ↵
    1. Linkermann A,
    2. De Zen F,
    3. Weinberg J,
    4. Kunzendorf U,
    5. Krautwald S
    : Programmed necrosis in acute kidney injury. Nephrol Dial Transplant 27: 3412–3419, 2012pmid:22942173
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 25 (12)
Journal of the American Society of Nephrology
Vol. 25, Issue 12
December 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Regulated Cell Death in AKI
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Regulated Cell Death in AKI
Andreas Linkermann, Guochun Chen, Guie Dong, Ulrich Kunzendorf, Stefan Krautwald, Zheng Dong
JASN Dec 2014, 25 (12) 2689-2701; DOI: 10.1681/ASN.2014030262

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Regulated Cell Death in AKI
Andreas Linkermann, Guochun Chen, Guie Dong, Ulrich Kunzendorf, Stefan Krautwald, Zheng Dong
JASN Dec 2014, 25 (12) 2689-2701; DOI: 10.1681/ASN.2014030262
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Apoptosis—the Classic View of Regulated Cell Death in the Kidney
    • Regulated Necrosis
    • Relationship between Apoptosis and Regulated Necrosis
    • Targeting Renal Cell Death for AKI Therapy
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Ensuring the Equitable Advancement of American Kidney Health—the Need to Account for Socioeconomic Disparities in the ESRD Treatment Choices Model
  • New ‘Antigens’ in Membranous Nephropathy
  • Animal Model of Pregnancy after Acute Kidney Injury Mirrors the Human Observations
Show more Up Front Matters

Brief Review

  • HIV-Positive Kidney Donor Selection for HIV-Positive Transplant Recipients
  • The Labile Side of Iron Supplementation in CKD
  • Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression
Show more Brief Review

Cited By...

  • SOX9 promotes stress-responsive transcription of VGF nerve growth factor inducible gene in renal tubular epithelial cells
  • Gentamicin-Induced Acute Kidney Injury in an Animal Model Involves Programmed Necrosis of the Collecting Duct
  • Interleukin-22 mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury
  • SOX9 promotes stress-responsive transcription of VGF nerve growth factor inducible gene in kidney epithelial cells
  • Protein Kinase C-{delta} Mediates Kidney Tubular Injury in Cold Storage-Associated Kidney Transplantation
  • Macrophage-Derived Exosomal Mir-155 Regulating Cardiomyocyte Pyroptosis and Hypertrophy in Uremic Cardiomyopathy
  • Integrin-Linked Kinase Deficiency in Collecting Duct Principal Cell Promotes Necroptosis of Principal Cell and Contributes to Kidney Inflammation and Fibrosis
  • RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress
  • Bif-1 Interacts with Prohibitin-2 to Regulate Mitochondrial Inner Membrane during Cell Stress and Apoptosis
  • Caspase-3 Is a Pivotal Regulator of Microvascular Rarefaction and Renal Fibrosis after Ischemia-Reperfusion Injury
  • Dynamin-Related Protein 1 Deficiency Promotes Recovery from AKI
  • Inhibition of Reticulon-1A-Mediated Endoplasmic Reticulum Stress in Early AKI Attenuates Renal Fibrosis Development
  • mTOR Signaling Regulates Protective Activity of Transferred CD4+Foxp3+ T Cells in Repair of Acute Kidney Injury
  • MicroRNA-489 Induction by Hypoxia-Inducible Factor-1 Protects against Ischemic Kidney Injury
  • Caspase-1, but Not Caspase-3, Promotes Diabetic Nephropathy
  • Mitochondria in Kidney Injury: When the Power Plant Fails
  • Autophagy Induces Prosenescent Changes in Proximal Tubular S3 Segments
  • Cellular and Molecular Mechanisms of AKI
  • Inflammation in AKI: Current Understanding, Key Questions, and Knowledge Gaps
  • Deficiency in the Formation of 20-Hydroxyeicosatetraenoic Acid Enhances Renal Ischemia-Reperfusion Injury
  • MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury
  • Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions
  • MG53-mediated cell membrane repair protects against acute kidney injury
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • acute renal failure
  • apoptosis
  • renal injury

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire